Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? / Boettiger, David C; Sabin, Caroline A; Grulich, Andrew; Nielsen, Lene Ryom; Bonnet, Fabrice; Reiss, Peter; Monforte, Antonella d'arminio; Kirk, Ole; Phillips, Andrew; Bower, Mark; Fätkenheuer, Gerd; Lundgren, Jens D; Law, Matthew; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group.

I: AIDS, Bind 30, Nr. 10, 19.06.2016, s. 1629-37.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Boettiger, DC, Sabin, CA, Grulich, A, Nielsen, LR, Bonnet, F, Reiss, P, Monforte, AD, Kirk, O, Phillips, A, Bower, M, Fätkenheuer, G, Lundgren, JD, Law, M & Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group 2016, 'Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?', AIDS, bind 30, nr. 10, s. 1629-37. https://doi.org/10.1097/QAD.0000000000001053

APA

Boettiger, D. C., Sabin, C. A., Grulich, A., Nielsen, L. R., Bonnet, F., Reiss, P., Monforte, A. D., Kirk, O., Phillips, A., Bower, M., Fätkenheuer, G., Lundgren, J. D., Law, M., & Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group (2016). Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS, 30(10), 1629-37. https://doi.org/10.1097/QAD.0000000000001053

Vancouver

Boettiger DC, Sabin CA, Grulich A, Nielsen LR, Bonnet F, Reiss P o.a. Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals? AIDS. 2016 jun. 19;30(10):1629-37. https://doi.org/10.1097/QAD.0000000000001053

Author

Boettiger, David C ; Sabin, Caroline A ; Grulich, Andrew ; Nielsen, Lene Ryom ; Bonnet, Fabrice ; Reiss, Peter ; Monforte, Antonella d'arminio ; Kirk, Ole ; Phillips, Andrew ; Bower, Mark ; Fätkenheuer, Gerd ; Lundgren, Jens D ; Law, Matthew ; Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group. / Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?. I: AIDS. 2016 ; Bind 30, Nr. 10. s. 1629-37.

Bibtex

@article{00f79d0ec836489ca5bc14e7345b0d25,
title = "Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?",
abstract = "OBJECTIVE: Nelfinavir exhibits potent anticancer properties against a range of tumours. However, in 2006/2007, nelfinavir supplies were accidently contaminated with a carcinogen. This analysis investigated the association between nelfinavir use and cancer risk in HIV-positive persons.DESIGN: Observational cohort study.METHODS: D:A:D study data was analysed using Poisson regression models to examine associations between cancer incidence and cumulative nelfinavir exposure, current nelfinavir exposure, and exposure to nelfinavir between 1 July 2006-30 June 2007.RESULTS: A total of 42 006 individuals (50% white, 73% male) contributed 303 005 person-years of follow-up between 1 January 2004 and 1 February 2014. At study enrolment, median age was 40 [interquartile range (IQR) 33-46] years and 8305 individuals had a history of nelfinavir use [median duration 1.7 (IQR 0.7-3.4) years]. During follow-up, nelfinavir was used by 2476 individuals for a median of 1.7 (IQR 0.7-3.8) years; 1063 were exposed to nelfinavir between 1 July 2006 and 30 June 2007. Overall, 2279 cancers were diagnosed at a rate of 0.75 [95% confidence interval (95% CI) 0.72-0.78] per 100 person-years. Neither greater cumulative exposure to nelfinavir [adjusted risk ratio (aRR) 0.93 for every additional 5 years, 95% CI 0.82-1.06, P = 0.26] nor current use of nelfinavir (aRR 0.98 vs other protease inhibitor use, 95% CI 0.68-1.41, P = 0.92) were associated with cancer risk. The adjusted risk of cancer for participants exposed to nelfinavir between 1 July 2006 and 30 June 2007 compared to those receiving other treatment over this period was 1.07 (95% CI 0.78-1.46, P = 0.68).CONCLUSION: Nelfinavir use was not associated with a lower cancer incidence than other protease inhibitor regimens. As of February 2014, exposure to the 2006/2007 contamination of nelfinavir does not appear to be associated with increased cancer incidence.",
keywords = "Journal Article",
author = "Boettiger, {David C} and Sabin, {Caroline A} and Andrew Grulich and Nielsen, {Lene Ryom} and Fabrice Bonnet and Peter Reiss and Monforte, {Antonella d'arminio} and Ole Kirk and Andrew Phillips and Mark Bower and Gerd F{\"a}tkenheuer and Lundgren, {Jens D} and Matthew Law and {Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group}",
year = "2016",
month = jun,
day = "19",
doi = "10.1097/QAD.0000000000001053",
language = "English",
volume = "30",
pages = "1629--37",
journal = "AIDS",
issn = "1350-2840",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "10",

}

RIS

TY - JOUR

T1 - Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?

AU - Boettiger, David C

AU - Sabin, Caroline A

AU - Grulich, Andrew

AU - Nielsen, Lene Ryom

AU - Bonnet, Fabrice

AU - Reiss, Peter

AU - Monforte, Antonella d'arminio

AU - Kirk, Ole

AU - Phillips, Andrew

AU - Bower, Mark

AU - Fätkenheuer, Gerd

AU - Lundgren, Jens D

AU - Law, Matthew

AU - Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group

PY - 2016/6/19

Y1 - 2016/6/19

N2 - OBJECTIVE: Nelfinavir exhibits potent anticancer properties against a range of tumours. However, in 2006/2007, nelfinavir supplies were accidently contaminated with a carcinogen. This analysis investigated the association between nelfinavir use and cancer risk in HIV-positive persons.DESIGN: Observational cohort study.METHODS: D:A:D study data was analysed using Poisson regression models to examine associations between cancer incidence and cumulative nelfinavir exposure, current nelfinavir exposure, and exposure to nelfinavir between 1 July 2006-30 June 2007.RESULTS: A total of 42 006 individuals (50% white, 73% male) contributed 303 005 person-years of follow-up between 1 January 2004 and 1 February 2014. At study enrolment, median age was 40 [interquartile range (IQR) 33-46] years and 8305 individuals had a history of nelfinavir use [median duration 1.7 (IQR 0.7-3.4) years]. During follow-up, nelfinavir was used by 2476 individuals for a median of 1.7 (IQR 0.7-3.8) years; 1063 were exposed to nelfinavir between 1 July 2006 and 30 June 2007. Overall, 2279 cancers were diagnosed at a rate of 0.75 [95% confidence interval (95% CI) 0.72-0.78] per 100 person-years. Neither greater cumulative exposure to nelfinavir [adjusted risk ratio (aRR) 0.93 for every additional 5 years, 95% CI 0.82-1.06, P = 0.26] nor current use of nelfinavir (aRR 0.98 vs other protease inhibitor use, 95% CI 0.68-1.41, P = 0.92) were associated with cancer risk. The adjusted risk of cancer for participants exposed to nelfinavir between 1 July 2006 and 30 June 2007 compared to those receiving other treatment over this period was 1.07 (95% CI 0.78-1.46, P = 0.68).CONCLUSION: Nelfinavir use was not associated with a lower cancer incidence than other protease inhibitor regimens. As of February 2014, exposure to the 2006/2007 contamination of nelfinavir does not appear to be associated with increased cancer incidence.

AB - OBJECTIVE: Nelfinavir exhibits potent anticancer properties against a range of tumours. However, in 2006/2007, nelfinavir supplies were accidently contaminated with a carcinogen. This analysis investigated the association between nelfinavir use and cancer risk in HIV-positive persons.DESIGN: Observational cohort study.METHODS: D:A:D study data was analysed using Poisson regression models to examine associations between cancer incidence and cumulative nelfinavir exposure, current nelfinavir exposure, and exposure to nelfinavir between 1 July 2006-30 June 2007.RESULTS: A total of 42 006 individuals (50% white, 73% male) contributed 303 005 person-years of follow-up between 1 January 2004 and 1 February 2014. At study enrolment, median age was 40 [interquartile range (IQR) 33-46] years and 8305 individuals had a history of nelfinavir use [median duration 1.7 (IQR 0.7-3.4) years]. During follow-up, nelfinavir was used by 2476 individuals for a median of 1.7 (IQR 0.7-3.8) years; 1063 were exposed to nelfinavir between 1 July 2006 and 30 June 2007. Overall, 2279 cancers were diagnosed at a rate of 0.75 [95% confidence interval (95% CI) 0.72-0.78] per 100 person-years. Neither greater cumulative exposure to nelfinavir [adjusted risk ratio (aRR) 0.93 for every additional 5 years, 95% CI 0.82-1.06, P = 0.26] nor current use of nelfinavir (aRR 0.98 vs other protease inhibitor use, 95% CI 0.68-1.41, P = 0.92) were associated with cancer risk. The adjusted risk of cancer for participants exposed to nelfinavir between 1 July 2006 and 30 June 2007 compared to those receiving other treatment over this period was 1.07 (95% CI 0.78-1.46, P = 0.68).CONCLUSION: Nelfinavir use was not associated with a lower cancer incidence than other protease inhibitor regimens. As of February 2014, exposure to the 2006/2007 contamination of nelfinavir does not appear to be associated with increased cancer incidence.

KW - Journal Article

U2 - 10.1097/QAD.0000000000001053

DO - 10.1097/QAD.0000000000001053

M3 - Journal article

C2 - 26854812

VL - 30

SP - 1629

EP - 1637

JO - AIDS

JF - AIDS

SN - 1350-2840

IS - 10

ER -

ID: 164823088